David Rintell

David Rintell is a seasoned professional in patient advocacy with extensive experience in the healthcare sector. Since November 2017, David has served as the Head of Patient Advocacy at BridgeBio, focusing on engaging patients, families, and caregivers in the drug development process. Prior to this role, David was the Head of Global Patient Advocacy for Rare Diseases at Sanofi Genzyme from November 2015 to November 2017, where responsibilities included fostering collaborations with patient communities. David's background also includes work as an Adjunct Professor at Brandeis University and roles as a psychologist at both Partners Multiple Sclerosis Center and Partners Pediatric Multiple Sclerosis Center. Additionally, David contributed to the Foundation for Neurologic Diseases and served on the Clinical Advisory Committee for the National MS Society. David earned an Ed.D. in Counseling Psychology from Boston University.